A new study demonstrates that the combination of lenalidomide (Revlimid) and obinutuzumab (Gazyva) is effective and ...

Key biomarkers identified can now predict disability progression in multiple sclerosis, offering potential for more ...

HANSIZHUANG ® (serplulimab) was the first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC – ...

Among 282 patients with pediatric-onset MS, 39% started high-efficacy therapy early (at ages 12-17), and 61% started late ...

The decision to discontinue BTK inhibitor treatment for CLL is complex, with emerging data suggesting that time-limited ...

Celltrion’s biosimilar marketing strategy in Europe has got seriously confusing after the firm asked to market its rituximab near-copy under four different brands. Its biosimilar of Roche’s ...

A study presented at ECTRIMS 2024 has identified critical biomarkers that can predict disability worsening in multiple ...

A team of researchers has identified critical biomarkers that can predict disability worsening in people with multiple ...

The incidence of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis increases with age.1 Despite this trend, ...

Can monoclonal antibodies fight antimicrobial resistance? Yes! Scientists believe they could be the answer to superbugs like ...

A study has revealed significant therapeutic inertia in the treatment of women with multiple sclerosis (MS), highlighting ...